Novo Nordisk A/S (NVO) Financials
PeriodQ2 FY2026
Published
Novo Nordisk reported $12.22 billion in net sales for Q2 FY2026, the quarter ended June 30, 2026, up 4.6% from a year earlier in US dollar terms, against a year-ago quarter that included a one-off release of a US 340B rebate provision. Net income was $3.27 billion, down 18.9% in US dollar terms, and diluted earnings per share were $0.74, after non-cash impairments on intangible pipeline assets, including the terminated monlunabant programme, raised research and development costs. On the company's adjusted measure, which excludes impairment losses and amortisation of intangible assets as well as US 340B provision reversals, diluted earnings per share were $0.96, up 7.5% in US dollar terms.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $12,215,487,373 | up 4.6% |
| Net income | $3,266,625,019 | down 18.9% |
| Diluted EPS | $0.74 | down 18.4% |
| Adjusted diluted EPS | $0.96 | up 7.5% |
Company details
| Name | Novo Nordisk A S |
|---|---|
| Ticker | NVO |
| CIK | 0000353278 |
| Exchange | NYSE |
| State | Denmark |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
| Latest period covered | Q2 FY2026, ended 2026-06-30, 6-K, accession 0000353278-26-000023 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 6-K around 2026-11-04 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included, plus a figure_sources block linking each figure the filing tags to the line that prints it.
- 20-F and 6-K summaryPage Qualitative synthesis of the latest 20-F + 6-K: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 6-K filings and eventsPage Digest of material 6-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Novo Nordisk A/S Q2 FY2026
How much revenue did Novo Nordisk make in Q2 FY2026?
Novo Nordisk reported $12.22 billion in net sales for Q2 FY2026, the quarter ended June 30, 2026, up 4.6% from $11.68 billion a year earlier in US dollar terms. The year-ago quarter included a one-off release of a US 340B rebate provision; the latest quarter included none.
Why did Novo Nordisk's net income fall in Q2 FY2026?
Novo Nordisk's net income for Q2 FY2026 was $3.27 billion, down 18.9% from $4.03 billion a year earlier in US dollar terms. The quarter absorbed non-cash impairments on intangible pipeline assets, including the terminated monlunabant programme, booked in research and development costs, and the year-ago quarter's sales had been lifted by a one-off US 340B rebate provision release.
What were Novo Nordisk's earnings per share in Q2 FY2026?
Novo Nordisk's diluted earnings per share for Q2 FY2026 were $0.74, down 18.4% from $0.91 a year earlier in US dollar terms. Each Novo Nordisk American depositary receipt represents one B share, so the figure is also per ADR.
What were Novo Nordisk's adjusted earnings per share in Q2 FY2026?
Novo Nordisk's adjusted diluted earnings per share for Q2 FY2026 were $0.96, up 7.5% from $0.90 a year earlier in US dollar terms. The company's adjusted measure excludes impairment losses and amortisation of intangible assets as well as US 340B provision reversals.
Where can I get Novo Nordisk A/S (NVO) financial data in machine-readable form?
Ticker Scout publishes Novo Nordisk A/S's financial statements as JSON at https://tickerscout.ai/nvo/financials.json, free, with no API key and no signup. The 20-F and 6-K narrative and the 6-K events digest are published as Markdown at https://tickerscout.ai/nvo/narrative.md and https://tickerscout.ai/nvo/events.md. Novo Nordisk A/S's SEC CIK is 0000353278. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Novo Nordisk A/S (NVO) next file with the SEC?
Novo Nordisk A/S (NVO) is expected to file its next Form 6-K with the SEC on or around November 4, 2026. That date is a projection rather than a company-announced date: it is derived from Novo Nordisk A/S's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 6-K for Q2 FY2026, the period ended 2026-06-30, SEC accession 0000353278-26-000023.
Related companies
How this page was built
This page was built from Novo Nordisk A/S's own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names four such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.